Literature DB >> 27867497

Murine models of breast cancer bone metastasis.

Laura E Wright1, Penelope D Ottewell2, Nadia Rucci3, Olivier Peyruchaud4, Gabriel M Pagnotti5, Antonella Chiechi1, Jeroen T Buijs6, Julie A Sterling7.   

Abstract

Bone metastases cause significant morbidity and mortality in late-stage breast cancer patients and are currently considered incurable. Investigators rely on translational models to better understand the pathogenesis of skeletal complications of malignancy in order to identify therapeutic targets that may ultimately prevent and treat solid tumor metastasis to bone. Many experimental models of breast cancer bone metastases are in use today, each with its own caveats. In this methods review, we characterize the bone phenotype of commonly utilized human- and murine-derived breast cell lines that elicit osteoblastic and/or osteolytic destruction of bone in mice and report methods for optimizing tumor-take in murine models of bone metastasis. We then provide protocols for four of the most common xenograft and syngeneic inoculation routes for modeling breast cancer metastasis to the skeleton in mice, including the intra-cardiac, intra-arterial, orthotopic and intra-tibial methods of tumor cell injection. Recommendations for in vivo and ex vivo assessment of tumor progression and bone destruction are provided, followed by discussion of the strengths and limitations of the available tools and translational models that aid investigators in the study of breast cancer metastasis to bone.

Entities:  

Year:  2016        PMID: 27867497      PMCID: PMC5108088          DOI: 10.1038/bonekey.2016.31

Source DB:  PubMed          Journal:  Bonekey Rep        ISSN: 2047-6396


  56 in total

Review 1.  Metastasis to bone: causes, consequences and therapeutic opportunities.

Authors:  Gregory R Mundy
Journal:  Nat Rev Cancer       Date:  2002-08       Impact factor: 60.716

2.  TWIST1 expression in breast cancer cells facilitates bone metastasis formation.

Authors:  Martine Croset; Delphine Goehrig; Agnieszka Frackowiak; Edith Bonnelye; Stéphane Ansieau; Alain Puisieux; Philippe Clézardin
Journal:  J Bone Miner Res       Date:  2014-08       Impact factor: 6.741

3.  Breast cancer cells interact with osteoblasts to support osteoclast formation.

Authors:  R J Thomas; T A Guise; J J Yin; J Elliott; N J Horwood; T J Martin; M T Gillespie
Journal:  Endocrinology       Date:  1999-10       Impact factor: 4.736

4.  Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2.

Authors:  T Yoneda; A Sasaki; C Dunstan; P J Williams; F Bauss; Y A De Clerck; G R Mundy
Journal:  J Clin Invest       Date:  1997-05-15       Impact factor: 14.808

5.  Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease.

Authors:  S L Dallas; I R Garrett; B O Oyajobi; M R Dallas; B F Boyce; F Bauss; J Radl; G R Mundy
Journal:  Blood       Date:  1999-03-01       Impact factor: 22.113

Review 6.  Skeletal complications of malignancy.

Authors:  R E Coleman
Journal:  Cancer       Date:  1997-10-15       Impact factor: 6.860

7.  Establishment and characterization of three new continuous cell lines derived from human breast carcinomas.

Authors:  L W Engel; N A Young; T S Tralka; M E Lippman; S J O'Brien; M J Joyce
Journal:  Cancer Res       Date:  1978-10       Impact factor: 12.701

8.  Breast cancer metastasis to bone: evaluation of bioluminescent imaging and microSPECT/CT for detecting bone metastasis in immunodeficient mice.

Authors:  S Cowey; A A Szafran; J Kappes; K R Zinn; G P Siegal; R A Desmond; H Kim; L Evans; R W Hardy
Journal:  Clin Exp Metastasis       Date:  2007-05-31       Impact factor: 5.150

9.  Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo.

Authors:  Penelope D Ottewell; Ning Wang; Hannah K Brown; Kimberly J Reeves; C Anne Fowles; Peter I Croucher; Colby L Eaton; Ingunn Holen
Journal:  Clin Cancer Res       Date:  2014-03-31       Impact factor: 12.531

10.  Excess TGF-β mediates muscle weakness associated with bone metastases in mice.

Authors:  David L Waning; Khalid S Mohammad; Steven Reiken; Wenjun Xie; Daniel C Andersson; Sutha John; Antonella Chiechi; Laura E Wright; Alisa Umanskaya; Maria Niewolna; Trupti Trivedi; Sahba Charkhzarrin; Pooja Khatiwada; Anetta Wronska; Ashley Haynes; Maria Serena Benassi; Frank A Witzmann; Gehua Zhen; Xiao Wang; Xu Cao; G David Roodman; Andrew R Marks; Theresa A Guise
Journal:  Nat Med       Date:  2015-10-12       Impact factor: 53.440

View more
  42 in total

Review 1.  Breast Cancer Dormancy in Bone.

Authors:  Miranda E Clements; Rachelle W Johnson
Journal:  Curr Osteoporos Rep       Date:  2019-10       Impact factor: 5.096

2.  Characterization of Cancer-Induced Nociception in a Murine Model of Breast Carcinoma.

Authors:  Amanda Spring de Almeida; Flávia Karine Rigo; Samira Dal-Toé De Prá; Alessandra Marcone Milioli; Diéssica Padilha Dalenogare; Gabriele Cheiran Pereira; Camila Dos Santos Ritter; Diulle Spat Peres; Caren Tatiane de David Antoniazzi; Carolina Stein; Rafael Noal Moresco; Sara Marchesan Oliveira; Gabriela Trevisan
Journal:  Cell Mol Neurobiol       Date:  2019-03-08       Impact factor: 5.046

3.  Skeletal impact of 17β-estradiol in T cell-deficient mice: age-dependent bone effects and osteosarcoma formation.

Authors:  Julia N Cheng; Jennifer B Frye; Susan A Whitman; Janet L Funk
Journal:  Clin Exp Metastasis       Date:  2019-12-20       Impact factor: 5.150

4.  Multiscale characterization of the mineral phase at skeletal sites of breast cancer metastasis.

Authors:  Frank He; Aaron E Chiou; Hyun Chae Loh; Maureen Lynch; Bo Ri Seo; Young Hye Song; Min Joon Lee; Rebecca Hoerth; Emely L Bortel; Bettina M Willie; Georg N Duda; Lara A Estroff; Admir Masic; Wolfgang Wagermaier; Peter Fratzl; Claudia Fischbach
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-18       Impact factor: 11.205

5.  Long-chain omega-3 polyunsaturated fatty acids decrease mammary tumor growth, multiorgan metastasis and enhance survival.

Authors:  Saraswoti Khadge; Geoffrey M Thiele; John Graham Sharp; Timothy R McGuire; Lynell W Klassen; Paul N Black; Concetta C DiRusso; Leah Cook; James E Talmadge
Journal:  Clin Exp Metastasis       Date:  2018-10-16       Impact factor: 5.150

6.  Metformin inhibits RANKL and sensitizes cancer stem cells to denosumab.

Authors:  Elisabet Cuyàs; Begoña Martin-Castillo; Joaquim Bosch-Barrera; Javier A Menendez
Journal:  Cell Cycle       Date:  2017-04-07       Impact factor: 4.534

Review 7.  Limiting tumor seeding as a therapeutic approach for metastatic disease.

Authors:  Asurayya Worrede; Olimpia Meucci; Alessandro Fatatis
Journal:  Pharmacol Ther       Date:  2019-03-12       Impact factor: 12.310

8.  uPAR antibody (huATN-658) and Zometa reduce breast cancer growth and skeletal lesions.

Authors:  Niaz Mahmood; Ani Arakelian; Haseeb Ahmed Khan; Imrana Tanvir; Andrew P Mazar; Shafaat A Rabbani
Journal:  Bone Res       Date:  2020-04-17       Impact factor: 13.567

9.  Systemic delivery of a Gli inhibitor via polymeric nanocarriers inhibits tumor-induced bone disease.

Authors:  Joseph P Vanderburgh; Kristin A Kwakwa; Thomas A Werfel; Alyssa R Merkel; Mukesh K Gupta; Rachelle W Johnson; Scott A Guelcher; Craig L Duvall; Julie A Rhoades
Journal:  J Control Release       Date:  2019-09-05       Impact factor: 9.776

10.  Tuning Ligand Density To Optimize Pharmacokinetics of Targeted Nanoparticles for Dual Protection against Tumor-Induced Bone Destruction.

Authors:  Joseph Vanderburgh; Jordan L Hill; Mukesh K Gupta; Kristin A Kwakwa; Sean K Wang; Kathleen Moyer; Sean K Bedingfield; Alyssa R Merkel; Richard d'Arcy; Scott A Guelcher; Julie A Rhoades; Craig L Duvall
Journal:  ACS Nano       Date:  2020-01-08       Impact factor: 15.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.